A patient on buprenorphine for opioid use disorder presents to the emergency department in severe pain after a motor vehicle accident. The treating team struggles with adequate analgesic dosing. What is the pharmacological reason for this difficulty?

• A Buprenorphine is a full mu-opioid agonist that causes tolerance; extremely high doses of additional opioids are needed to overcome tolerance
• B Buprenorphine has no analgesic activity; pain in these patients must be managed entirely with non-opioid multimodal analgesia
• C Buprenorphine is a partial mu-opioid agonist with very high mu-receptor binding affinity (extremely slow off-rate) and a 'ceiling effect' — it occupies mu receptors without full activation and prevents additional full agonist opioids from binding at therapeutic doses ✓
• D Buprenorphine causes downregulation of all opioid receptor types, reducing response to any exogenous opioid regardless of receptor

Explanation

Buprenorphine is a partial agonist at mu-opioid receptors with extraordinarily high binding affinity (sub-nanomolar Ki) and extremely slow dissociation from the receptor ('slow off-rate'), producing long receptor occupancy. Because it is a partial agonist, it produces submaximal activation regardless of dose (ceiling effect for both analgesia and respiratory depression). When buprenorphine occupies mu receptors, additional full agonists (morphine, fentanyl) have limited access to these receptors and, when they do bind to residual unoccupied receptors, still compete poorly due to the high buprenorphine affinity. Management strategies include: continuing maintenance buprenorphine and adding high-dose full agonists (with monitoring), or switching to methadone, or multimodal non-opioid analgesia with regional techniques.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.